Actively Recruiting
NOX4 and Related Biomarkers in ADPKD
Led by Mayo Clinic · Updated on 2026-01-09
60
Participants Needed
1
Research Sites
336 weeks
Total Duration
On this page
Sponsors
M
Mayo Clinic
Lead Sponsor
P
Polycystic Kidney Disease Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).
CONDITIONS
Official Title
NOX4 and Related Biomarkers in ADPKD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of autosomal dominant polycystic kidney disease (ADPKD) based on Ravine et al. criteria
- Class 1 A-E disease severity according to imaging classification
- Male or female aged 15 to 40 years
- Estimated glomerular filtration rate (eGFR) greater than 70 mL/min/1.73 m2
- Ability to provide written informed consent
You will not qualify if you...
- Class 2 disease severity according to imaging classification
- Other systemic diseases affecting the kidney
- Diabetes mellitus
- Predicted urine protein excretion greater than 1 g/24 hours
- Use of antioxidants such as vitamins or Nrf2 activators
- Abnormal urinalysis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here